Physician profile
Sinnathurai Vasanthakumar
NPI 1598714479
$11,739.04
in general payments reported to CMS, 2019-2025
46 companies · $2,017 in 2025
The $2,017 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,683 · 2020: $885 · 2021: $1,844 · 2022: $1,777 · 2023: $1,838 · 2024: $1,695 · 2025: $2,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,550.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,550.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,344.05 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $1,257.47 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,049.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $971.38 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Amgen INC. | $815.82 | 2019-2025 | Evenity, Repatha, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $543.43 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $517.52 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $516.20 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $495.52 | 2019-2025 | |
| Astellas Pharma US INC | $425.04 | 2019-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $391.32 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $387.29 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $296.70 | 2019-2024 | Gardasil 9, Vaxneuvance, Capvaxive |
| Amarin Pharma, INC. | $196.61 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $194.38 | 2024-2025 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sinnathurai Vasanthakumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.